vs
Bloom Energy Corp（BE）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是Bloom Energy Corp的1.0倍（$772.1M vs $751.1M），Revvity净利率更高（12.7% vs 9.4%，领先3.3%），Bloom Energy Corp同比增速更快（130.4% vs 5.9%），过去两年Bloom Energy Corp的营收复合增速更高（51.7% vs 9.0%）
Bloom Energy Corp是一家能源技术企业，由印裔美国工程师、发明家、企业家KR·斯里达尔创立，他同时担任公司董事长兼首席执行官。斯里达尔此前曾任亚利桑那大学航空航天与机械工程教授、空间技术实验室主任，曾为NASA提供顾问服务，现为美国国家工程院院士。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
BE vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.0倍
$751.1M
营收增速更快
BE
高出124.5%
5.9%
净利率更高
RVTY
高出3.3%
9.4%
两年增速更快
BE
近两年复合增速
9.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $751.1M | $772.1M |
| 净利润 | $70.7M | $98.4M |
| 毛利率 | 30.0% | — |
| 营业利润率 | 17.3% | 14.5% |
| 净利率 | 9.4% | 12.7% |
| 营收同比 | 130.4% | 5.9% |
| 净利润同比 | — | 3.9% |
| 每股收益（稀释后） | $0.44 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BERVTY
| Q1 26 | $751.1M | — | ||
| Q4 25 | $772.8M | $772.1M | ||
| Q3 25 | $513.3M | $698.9M | ||
| Q2 25 | $396.3M | $720.3M | ||
| Q1 25 | $319.3M | $664.8M | ||
| Q4 24 | $567.0M | $729.4M | ||
| Q3 24 | $321.8M | $684.0M | ||
| Q2 24 | $326.5M | $691.7M |
净利润BERVTY
| Q1 26 | $70.7M | — | ||
| Q4 25 | $1.4M | $98.4M | ||
| Q3 25 | $-23.0M | $46.7M | ||
| Q2 25 | $-42.2M | $53.9M | ||
| Q1 25 | $-23.4M | $42.2M | ||
| Q4 24 | $105.2M | $94.6M | ||
| Q3 24 | $-14.6M | $94.4M | ||
| Q2 24 | $-61.2M | $55.4M |
毛利率BERVTY
| Q1 26 | 30.0% | — | ||
| Q4 25 | 31.0% | — | ||
| Q3 25 | 29.5% | 53.6% | ||
| Q2 25 | 27.0% | 54.5% | ||
| Q1 25 | 27.8% | 56.5% | ||
| Q4 24 | 38.7% | — | ||
| Q3 24 | 24.5% | 56.3% | ||
| Q2 24 | 21.0% | 55.7% |
营业利润率BERVTY
| Q1 26 | 17.3% | — | ||
| Q4 25 | 11.3% | 14.5% | ||
| Q3 25 | 1.5% | 11.7% | ||
| Q2 25 | -0.9% | 12.6% | ||
| Q1 25 | -6.0% | 10.9% | ||
| Q4 24 | 18.5% | 16.3% | ||
| Q3 24 | -3.0% | 14.3% | ||
| Q2 24 | -7.1% | 12.4% |
净利率BERVTY
| Q1 26 | 9.4% | — | ||
| Q4 25 | 0.2% | 12.7% | ||
| Q3 25 | -4.5% | 6.7% | ||
| Q2 25 | -10.6% | 7.5% | ||
| Q1 25 | -7.3% | 6.4% | ||
| Q4 24 | 18.5% | 13.0% | ||
| Q3 24 | -4.5% | 13.8% | ||
| Q2 24 | -18.7% | 8.0% |
每股收益（稀释后）BERVTY
| Q1 26 | $0.44 | — | ||
| Q4 25 | $99.91 | $0.86 | ||
| Q3 25 | $-100.00 | $0.40 | ||
| Q2 25 | $-0.18 | $0.46 | ||
| Q1 25 | $-0.10 | $0.35 | ||
| Q4 24 | $0.45 | $0.77 | ||
| Q3 24 | $-0.06 | $0.77 | ||
| Q2 24 | $-0.27 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $948.0K | $7.3B |
| 总资产 | $4.7B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BERVTY
| Q1 26 | — | — | ||
| Q4 25 | $2.5B | $919.9M | ||
| Q3 25 | $595.1M | $931.4M | ||
| Q2 25 | $574.8M | $991.8M | ||
| Q1 25 | $794.8M | $1.1B | ||
| Q4 24 | $802.9M | $1.2B | ||
| Q3 24 | $495.7M | $1.2B | ||
| Q2 24 | $581.7M | $2.0B |
总债务BERVTY
| Q1 26 | — | — | ||
| Q4 25 | $2.6B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | $1.1B | — | ||
| Q2 24 | $1.1B | — |
股东权益BERVTY
| Q1 26 | $948.0K | — | ||
| Q4 25 | $768.6M | $7.3B | ||
| Q3 25 | $653.1M | $7.4B | ||
| Q2 25 | $594.6M | $7.6B | ||
| Q1 25 | $578.3M | $7.6B | ||
| Q4 24 | $562.5M | $7.7B | ||
| Q3 24 | $430.9M | $7.9B | ||
| Q2 24 | $423.3M | $7.9B |
总资产BERVTY
| Q1 26 | $4.7B | — | ||
| Q4 25 | $4.4B | $12.2B | ||
| Q3 25 | $2.6B | $12.1B | ||
| Q2 25 | $2.5B | $12.4B | ||
| Q1 25 | $2.6B | $12.4B | ||
| Q4 24 | $2.7B | $12.4B | ||
| Q3 24 | $2.6B | $12.8B | ||
| Q2 24 | $2.5B | $13.4B |
负债/权益比BERVTY
| Q1 26 | — | — | ||
| Q4 25 | 3.41× | — | ||
| Q3 25 | 1.73× | — | ||
| Q2 25 | 1.91× | — | ||
| Q1 25 | 1.96× | — | ||
| Q4 24 | 2.01× | — | ||
| Q3 24 | 2.62× | — | ||
| Q2 24 | 2.66× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流BERVTY
| Q1 26 | — | — | ||
| Q4 25 | $418.1M | $182.0M | ||
| Q3 25 | $19.7M | $138.5M | ||
| Q2 25 | $-213.1M | $134.3M | ||
| Q1 25 | $-110.7M | $128.2M | ||
| Q4 24 | $484.2M | $174.2M | ||
| Q3 24 | $-69.5M | $147.9M | ||
| Q2 24 | $-175.5M | $158.6M |
自由现金流BERVTY
| Q1 26 | — | — | ||
| Q4 25 | $395.1M | $161.8M | ||
| Q3 25 | $7.4M | $120.0M | ||
| Q2 25 | $-220.4M | $115.5M | ||
| Q1 25 | $-124.9M | $112.2M | ||
| Q4 24 | $473.1M | $149.8M | ||
| Q3 24 | $-83.8M | $125.6M | ||
| Q2 24 | $-187.5M | $136.6M |
自由现金流率BERVTY
| Q1 26 | — | — | ||
| Q4 25 | 51.1% | 21.0% | ||
| Q3 25 | 1.4% | 17.2% | ||
| Q2 25 | -55.6% | 16.0% | ||
| Q1 25 | -39.1% | 16.9% | ||
| Q4 24 | 83.4% | 20.5% | ||
| Q3 24 | -26.0% | 18.4% | ||
| Q2 24 | -57.4% | 19.7% |
资本支出强度BERVTY
| Q1 26 | — | — | ||
| Q4 25 | 3.0% | 2.6% | ||
| Q3 25 | 2.4% | 2.6% | ||
| Q2 25 | 1.8% | 2.6% | ||
| Q1 25 | 4.5% | 2.4% | ||
| Q4 24 | 2.0% | 3.4% | ||
| Q3 24 | 4.4% | 3.3% | ||
| Q2 24 | 3.7% | 3.2% |
现金转化率BERVTY
| Q1 26 | — | — | ||
| Q4 25 | 293.18× | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | — | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | 4.60× | 1.84× | ||
| Q3 24 | — | 1.57× | ||
| Q2 24 | — | 2.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BE
| Product | $653.3M | 87% |
| Service | $61.9M | 8% |
| Installation | $25.9M | 3% |
| Electricity | $9.9M | 1% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
